VRTX — VERTEX PHARMACEUTICALS INC / MA

—
Nasdaq · Health Care · Pharmaceuticals · CIK 875320 ·
Last close
$534.20
Market Cap
$135.44B
52W High
$568.67
52W Low
$412.27
ADV30
1,512,144
Next earnings
2026-11-02

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 3,440,800,000 2,914,700,000 750,000,000 653,600,000 32,736,300,000 4,979,300,000 11,828,900,000
Jun 2026 3,333,900,000 2,844,700,000 1,268,700,000 1,099,800,000 27,423,300,000 6,143,500,000 7,175,400,000
Mar 2026 2,986,900,000 2,594,100,000 1,138,800,000 1,031,400,000 26,484,400,000 5,492,900,000 7,122,500,000
Dec 2025 3,190,000,000 2,724,000,000 1,130,300,000 1,191,100,000 25,643,000,000 5,084,800,000 6,977,200,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$3,694,600,000
Investing CF
$-6,866,400,000
Financing CF
$3,254,200,000
CapEx
$-492,300,000
Dividends Paid
—
Buybacks
$-1,376,100,000
EPS Diluted TTM
$15.54
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$16,344,800,000
Inventory
$2,245,300,000
Receivables
$2,311,000,000
ST Investments
$1,324,000,000
EBIT TTM
$4,561,200,000
Pretax Income TTM
$4,759,100,000
Interest Exp TTM
$46,300,000
Analysts
28

Yahoo Snapshot (yfinance, live)

Total Revenue
$12,951,600,128
EBITDA
$5,100,800,000
Free Cash Flow
$2,337,787,392
Enterprise Value
$138,883,022,848
Total Cash
$6,303,300,096
Total Debt
$6,478,400,000
Shares Out
253,537,674
Trailing EPS
$15.54
Book Value
$82.47
ROE
20.8%
ROA
10.6%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 12,001,300,000 4,554,400,000 3,953,200,000 25,643,000,000 6,977,200,000 18,665,800,000 3,631,400,000
Dec 2024 11,020,100,000 -233,400,000 -535,600,000 22,533,200,000 6,123,600,000 16,409,600,000 -492,600,000
Dec 2023 9,869,200,000 3,780,400,000 3,619,600,000 22,730,200,000 5,149,800,000 17,580,400,000 3,537,300,000
Dec 2022 8,930,700,000 4,249,900,000 3,322,000,000 18,150,900,000 4,238,200,000 13,912,700,000 4,129,900,000

TTM Snapshot

Revenues TTM
$12,587,200,000
NetIncome TTM
$4,405,200,000
OpCashFlow TTM
—
Assets (Latest)
$27,423,300,000
Forward EPS
$19.92

Peers — same industry

TickerNameMarket CapLastDaily %
NVO NOVO NORDISK A S $136.10B $40.70 —
BMY BRISTOL MYERS SQUIBB CO $125.40B $61.35 —
SNY Sanofi $113.89B $47.53 —
PFE PFIZER INC $162.27B $28.47 —
ABT ABBOTT LABORATORIES $181.35B $104.71 —

News headlines (Yahoo Finance, 1h cache)

Should You Pick Vertex Stock Over Its Biotech Rivals?
2026-11-18 17:13 · Yahoo
Genomics Ltd. Announces Extension of Strategic Drug Discovery Collaboration with Vertex Pharmaceuticals
2026-11-18 09:43 · Yahoo
Vertex Pharmaceuticals (VRTX) Stock May Be Undervalued After Its 187% Run
2026-11-18 05:13 · Yahoo
Vertex Pharmaceuticals (VRTX) Could Be 11% Undervalued On Late Stage Pipeline Focus
2026-11-18 03:12 · Yahoo
Johnson & Johnson vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy for 2027?
2026-11-17 23:47 · Yahoo
Vertex Pharmaceuticals Eyes Nov. 30 Kidney Drug Decision as 2027 Pipeline Milestones Loom
2026-11-17 20:12 · Yahoo
Biotechnology Market Companies 2027 Analysis: Amgen, Gilead, Regeneron, Vertex and Moderna Post Strong 2026 Results as Billion-Dollar Deals Reshape a Market Headed for USD 6.34 Trillion by 2035
2026-11-17 15:00 · Yahoo
Vertex Pharmaceuticals Prepares for Key Kidney Drug Decision as Pipeline Readouts Loom
2026-11-16 12:12 · Yahoo
Amgen vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy for 2027?
2026-11-13 23:02 · Yahoo
Vertex Resource Group Ltd. Reports Third Quarter 2026 Results
2026-11-12 22:35 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.